Startup spotlight

FwdFaster

FwdFaster AI – Redefining the Future with Expert-Powered AI

The Problem

Despite unlocking impressive efficiencies and reshaping how we navigate the world, the current AI paradigm’s focus on scale, speed and optimization fails to address today’s most pressing social, political, environmental and ethical challenges. Too often, long-term societal and planetary well-being are treated as secondary concerns or left out of the agenda altogether. In this dynamic, human experts are increasingly pushed into the passenger seat. Their judgment, contextual understanding and responsibility are overshadowed by systems designed to optimize for short-term performance rather than long-term public value. As a result, decisions that shape healthcare, policy, compliance, sustainability and safety risk are becoming automated without clear accountability and responsibility.

The Solution

FwdFaster AI calls for a paradigm shift in how AI systems are designed and deployed. Instead of replacing or sidelining experts, AI can strengthen their role, supporting human judgment rather than simulating it. This requires coordinated action at the European level to ensure that technological progress remains aligned with societal values, democratic principles and the public interest. By embedding AI within expert-led processes and grounding it in shared European standards and responsibilities, we can build systems and infrastructure that are not only powerful but also trustworthy, ethical and fit for long-term impact across European Member States and beyond.

Why now?

We are at a critical inflection point. An important crossroad. AI capabilities are advancing faster than the institutional frameworks, governance structures and professional practices needed to guide them responsibly and successfully. Decisions made today will shape how expertise, accountability, and public trust evolve for decades, having a great impact on society and our economy. Europe has a unique opportunity to lead, not by racing to automate everything, but by setting a global example for human-centered, expert-driven AI. The question is no longer whether AI will be integrated into high-stakes domains, but how and where. FwdFaster AI wants to ensure that this integration happens with experts firmly in the driver’s seat, exactly when it matters most.

What makes FwdFaster unique?

FwdFaster is unique because it combines advanced AI with an expert-in-the- loop approach to accelerate high-quality evidence synthesis, improving decision-making, driving innovation and validating promising solutions across a wide range of societally relevant domains. They have started this work in a large number of European projects (7) and (inter)national collaborations with companies and societal organisations. At the same time, they are building software and platform solutions to apply these learned lessons to a wider audience. For example, they conduct collaborative “Screenathon” models enabling experts and AI to rapidly screen massive volumes of scientific literature, building structured knowledge warehouses that make insights reusable and actionable over time. All rooted in open science and trustworthy AI principles.

Meet the Founders

Dr. Frans Folkvord is a behavioral and health scientist specialized in decision-making and the societal impact of technology and AI and is active in a large number of European projects. His work focuses on how digital technologies and AI systems influence human behavior, responsibility and trust, critical insights for designing AI that aligns with public values and long-term societal outcomes rather than short-term optimization. His is an associate professor at Tilburg University, a Technical Expert at the World Health Organization (WHO) and a fanatic athlete in his free time.

Prof. Dr. Rens van de Schoot is an internationally recognized methodologist and statistician, known for his work on evidence synthesis, research integrity and responsible data use. With deep experience at the intersection of science, policy and complex decision-making, he brings a rigorous perspective on how AI should support expert judgment in high-stakes domains. He is a professor on Collaborative AI at Utrecht University and a climber in his free time.

Ir. Jonathan de Bruin is an AI architect, entrepreneur and active research engineer in the open-source community. His work has made him one of the most downloaded Python developers worldwide, with a project recognized as critical infrastructure by the Python Software Foundation. He also designed ASReview LAB at Utrecht University, an open-source AI tool for literature screening. Jonathan focuses on keeping AI effective, capable and integrated into expert workflows. When not coding or researching, he enjoys inline skating at the park.

Follow FwdFaster AI on LinkedIn to stay up-to-date with their activities and to know more,visit https://www.fwdfaster.ai

Bactheravax - UNIIQ's 100th investment

Bactheravax, advancing innovative colon cancer treatment becomes UNIIQ’s 100th investment

UNIIQ marked a major milestone: its 100th investment. The fund announced a new stake in Bactheravax, a UtrechtInc associated startup developing an innovative vaccine concept aimed at improving the treatment of colon cancer.

Colon cancer continues to have a significant societal impact, with high mortality rates despite advances in care. Bactheravax is working on a novel, research-driven approach that could strengthen treatment options and improve patient outcomes.

We congratulate Bactheravax and we look forward to seeing how they progress and contribute to the future of cancer treatment.

 

Irati, Wido & Carina featured in FD Talenten 2026

🎉 Proud moment: FD Talenten highlights three UtrechtInc founders!

We’re thrilled to share that Irati, Wido and Carina, founders who started their jouneys with UtrechtInc, were recently featured in Het Financieele Dagblad’s FD Talenten coverage, celebrating young entrepreneurial talent driving innovation in the Netherlands.

Each of these founders is building something exciting:

  • Irati Beltrán Hernández, co-founder of Lumox is developing a therapy that targets tumors with unmatched precision, sparing healthy tissue, for patients who now face disfiguring surgery or have no treatment options at all.
  • Wido Heeman, founder of SPCTR is developing a medical device that aims to improve patient outcomes after cancer surgery by combining light with artificial intelligence. Their goal is to lower patient stress, reduce reoperations and reduce the stress on our healthcare system by making surgical time more efficient.
  • Carina Nieuwenweg, founder of Novya Biotech, a synthetic biology company, is developing scalable, fermentation-based pigments inspired by nature. They engineer yeast cells to produce high-quality colors that can replace polluting synthetic dyes and resource-intensive plant extraction.

Their inclusion among the FD Talenten speaks to the impact and promise of founders emerging from academic and research backgrounds and we’re proud to see their hard work and vision recognised on a national stage.

👏 A big congratulations to all three, UtrechtInc is cheering you on as you continue to grow and inspire!

Future Tech Ventures Backs SPCTR to Bring Real-Time AI to Cancer Surgery!

Future Tech Ventures Backs SPCTR to Bring Real-Time AI to Cancer Surgery!

Future Tech Ventures has invested in SPCTR, which is developing real-time AI tools to support surgeons during oncological operations.

Precision in cancer surgery is critically important, not just to remove the tumor, but to make sure cancerous tissue is fully excised while sparing healthy tissue. Traditionally, this “margin analysis” happens hours or even days after surgery, once pathology reports return. SPCTR aims to change that by bringing real-time AI-driven margin analysis directly into the operating room, helping surgeons make better decisions while the patient is still in surgery.

The investment from Future Tech Ventures supports SPCTR in advancing its technology and scaling its impact. By combining advanced AI with surgical workflows, this innovation could reduce the need for follow-up surgeries, improve patient outcomes, and accelerate how AI is deployed in clinical practice.

This is a great example of how Dutch startups at the intersection of AI and healthcare are attracting venture capital and pushing the boundaries of what’s possible in medical technology and it highlights the strength of the Netherlands as a hub for real-world AI innovation in life sciences.

Congratulations from UtrechtInc!

👉 Read the article : https://futuretechventures.nl/update/ai-in-de-operatiekamer-future-tech-ventures-investeert-in-spctr-voor-real-time-marge-analyse-bij-oncologische-chirurgie/

 

UtrechtInc x ICAT

UtrechtInc partners with ICAT (Innovation Center for Advanced Therapies) to offer full support to Life Sciences & MedTech innovators, all the way from ideation to early commercialisation!

Our strategic partnership with ICAT, creates a modular support system for startups working on next-generation medical technology and advanced therapeutics. With support from the Provincie Utrecht, our enhanced program offers an even stronger platform for life sciences & medical technology startups, helping founders bring innovative therapies to patients faster and smarter.

Located in Utrecht Science Park in Zeist, ICAT’s Open Innovation Facility welcomes startups at all stages of development, from ideas to established ventures, with access to state-of-the-art  infrastructure and field experts. This offer complements UtrechtInc’s dedicated mentorship, extensive business network expertise and guidance on market readiness, tech validation, corporate partners, matchmaking events, dedicated mentorship and an extensive business network.

What value does ICAT add to the UtrechtInc offering?

A fully equipped lab space in an open shared innovation environment; State-of-the art equipment for:

• Tissue engineering & biomaterials

• Histology & microscopy

• Cell and tissue analysis

• Viral vectors

• Cell expansion platforms

• 3D printing & Bioprinting platforms

🧠 Access to a team of experts: Regulatory, GMP compliance, Health Tech Assessment & Economics, QA, QC and Business Development.

Whether you’re building the next breakthrough in medical technology or advanced therapeutics, this collaboration helps you validate, scale and connect.

Call for Applications – Make It Matter Voucher Programme

🔔 Call for Applications – Make It Matter Voucher Programme 🔔

Researchers at Utrecht University and UMC Utrecht are invited to apply for the Make It Matter Voucher Programme, initiated by Utrecht Holdings.

This voucher supports early-stage technology validation and is designed to bridge the gap between academic discovery and commercial application. The programme enables researchers to validate commercial potential, increase Technology Readiness Level (TRL), and strengthen intellectual property (IP).

Key points:

• €25,000 voucher for 12-month proof-of-concept projects
• For early-stage technologies (not regular research projects)
• Success-based repayment: only repay if commercialisation is achieved
• Open to UU and UMCU employees with novel IP and commercial potential

📅 Application deadline: 12 March

Interested in turning your research into real-world impact?

Get in touch with the Make It Matter team or visit the website for more information.

Welcome Nishtha: our Marketing & Community Intern

Meet our new Marketing & Community Intern: Nishtha

We are happy to welcome Nishtha as our new Marketing and Community Intern. Currently studying New Media and Digital Culture at Utrecht University, she joins the team to support our community initiatives while expanding her marketing skills.

Nishtha is motivated by the process of turning complex problems into functional solutions. She says: “I have a lot of respect and appreciation for people who work on building solutions for real world problems! There is something so beautiful to come out of all the chaos and to witness those journeys would be an honour and a lesson”.

During her internship, she looks forward to exploring different roles within the startup ecosystem and learning firsthand how founders navigate the journey from idea to impact.

Outside of work, you will find her rolling on the floor over a stand-up, tearing up over drama and geeking out about Karl Marx (or just history, really), all while cooking some great vegan fusion!

We’re happy to have her on board!

Welcome Saif: our Startup Scout

Meet our new Startup Scout: Saif

We think that the best startups are built where technology meets human connection and that´s where we found our new Startup Scout, Saif Abdoelrazak.
Saif joins us with a background in Artificial Intelligence. After spending time at Bit developing AI prototypes for public organizations, he’s shifting his focus to the very beginning of the founder journey: scouting and supporting early-stage talents here at UtrechtInc.

What makes Saif a fit for our community isn’t just his technical expertise; it’s his ability to bring people together. You can also find him hosting storytelling nights at de Nijverheid, organizing potlucks for friends, engaging in long, deep coffee conversations and soaking up live music and creative communities.
Saif is here to listen, connect, and help founders turn “what if” into “what’s next.”

We are happy to have you in the incubator. 💛

Startup spotlight

Lumox

Congratulations to Lumox and the founders, Irati Beltrán Hernández and Sebas Pronk, on finalizing a license agreement with Utrecht Holdings for two foundational patents developed at Utrecht University. This agreement secures the exclusive rights to the core technology originating from Sabrina Oliveira’s research group, marking a critical step in transitioning this science from the lab to the clinic.

Securing intellectual property is a vital prerequisite for the investment required to fund large-scale drug production, safety studies, and clinical trials. This successful negotiation ensures that Lumox has the necessary framework to attract the capital needed to bring new therapies to patients, specifically targeting head and neck cancer.

This partnership serves as a model for effective tech transfer:
Market Readiness: Lumox gains the exclusivity needed to de-risk future investment.
Academic Impact: Utrecht University ensures its research reaches the public while maintaining a stake in its success.
Clinical Path: Breakthrough science moves closer to becoming a tangible treatment for patients.

A thank you to the team at Utrecht Holdings, including Danielle Counotte and Director Tessa Scharringhausen, for their collaborative approach to this deal. We look forward to seeing Lumox accelerate their development and move closer to their first clinical trials. 🥂

➡️ Read more here

Welcome Bas, new mentor

Exciting news for our community: we would like to welcome Bas Neggers as our newest mentor. 🧠

Bas brings experience at the intersection of Bio- and Medical Physics and Neuroscience. As a scientist-entrepreneur, he successfully led the UMC Utrecht spinoff Brain Science Tools BV from its ideation to its acquisition by MagVenture A/S from Denmark.

His work has been important in developing and marketing clinical applications for:
✔️ Advanced brain imaging
✔️ Neuromodulation
✔️ Translating complex research into scalable medical technology

Our startup founders have the opportunity to learn from someone who understands the journey from lab to market.